Sodium Methanesulfinate CAS 20277-69-4 Munditia >96.0%
Shanghai Ruifu Chemical Co., Ltd. est primarius fabrica sodium Methanesulfinates (CAS: 20277-69-4) cum qualitate alta.Ruifu Chemical traditio totius terrarum, quantitatis competitive pretium, optimum servitium, parvas et moles in promptu habere potest.Purchase Sodium Methanesulfinate,Please contact: alvin@ruifuchem.com
Nomen chemicum | Sodium Methanesulfinate |
Synonyma | Methanesulfinic Acidum Sodium Salis |
CAS Number | 20277-69-4 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | CH5NaO2S |
M. Pondus | 104.1 |
Liquescens punctum | 222.0~ 226.0' (decl.) |
Aqua Solubility | Solutum in aqua |
Sensitiva | Air Sensitiva & Hygroscopic |
COA & MSDS | Praesto |
Origin | Shanghai, China |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Alba vel Off-White Crystalli pulveris |
Puritas | >96.0% |
Damnum in siccitate | <1.00% |
Infrared Imaginis | Conformat ut Structure |
Proton NMR Spectrum | Conformat ut Structure |
Test Standard | Enterprise Standard |
Consuetudinem | Pharmaceutical Intermedia;Synthesis organica |
Periculum symbola | Xn - Noxia |
Periculum Codes | R22 - noxia absorptus |
R20/21/22 - Inspiratio noxia, in contactu cum cute et absorpta. | |
Salus Descriptio | S36/37 - indumentis tutelae idoneis gere et caestus. |
S24/25 - contactus cum cute et oculis fuge. | |
Consociatione Nationum IDs | 2811 |
WGK Germania | 3 |
Stipare Group | III |
Shanghai Ruifu Chemical Co., Ltd. copia mercatorum Sodium Methanesulfinate (CAS: 20277-69-4).Medium pharmaceuticum magni momenti est, quod in productione API adhiberi potest (CAS 231277-92-2) et (CAS 388082-78-8) API aliisve mediis.(CAS 388082-78-8), novum membrum ordinis inhibitorum RTK inhibitorum 4-anilinoquinazolini (RTKIs), sicut curationem oralem pro cancro pectori immissa est.Dualem affinitatem habet cum EGFR et HER2 tyrosinis kinasibus.Indicatur in compositione cum Capecitabine curandis aegris cum carcinomate provectio vel metastatico pectoris, cuius tumores HER2 superexprimunt et qui priora therapiam in anthracyclinam, taxaneum et trastuzumab receperunt.